Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 800

NCT06972459

ArmPopulationDoseWeeksEstimandWeight change
Orforglipron Dose 1Obesity or overweightn/rn/rn/rn/r
Orforglipron Dose 2Obesity or overweightn/rn/rn/rn/r
Orforglipron Dose 3Obesity or overweightn/rn/rn/rn/r
Orforglipron Dose 4Obesity or overweightn/rn/rn/rn/r
PlaceboObesity or overweightn/rn/rn/rn/r